Methods of Treating Inflammatory Diseases with Formula I and II Compounds

The USPTO published patent application US20260091026A1 disclosing compounds of Formula (I) and Formula (II) for treating inflammatory diseases. The application was filed on December 5, 2025, and published on April 2, 2026, with inventors Robert Joseph Moreau et al. The technical disclosure covers novel heterocyclic compounds, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and methods of using these compounds to treat inflammatory diseases and disorders (classified under CPC A61P 29/00).

This publication establishes a priority date and makes the technical disclosure publicly available. The document is informational in nature and does not create compliance obligations or deadlines. No immediate action is required by any party. This patent application publication does not grant any exclusive rights—the patent must still be examined and granted before any enforceable rights attach.